Group 1: Market Expansion Plans - The company is actively pursuing internationalization strategies in Africa, focusing on Nigeria and Tanzania for resource development and industrial empowerment [1] - Nigeria's lithium mining project aims to enhance resource development and create a supply chain for new energy [1] - The establishment of a GMP-compliant pharmaceutical production base in Africa is planned to meet local healthcare needs [1] Group 2: Pharmaceutical Excipients Industry - The company offers 127 types of pharmaceutical excipients, covering 32.87% of the 387 types listed in the Chinese Pharmacopoeia (2025 edition) [2] - Established supply relationships with over 3,000 domestic clients, indicating high product stickiness [2] - The company has received 12 "variety guardian" qualifications for pharmaceutical excipients from the National Pharmacopoeia Commission [2] Group 3: Financial Performance - In the first half of 2025, the company's revenue increased by 9.74%, with a net profit surge of 497.36%, reversing the losses of 2024 [6] - The revenue from the new energy sector reached 12,660.22 million yuan, accounting for 18.57% of total revenue, with a gross margin of 36.25% [3] - Sales of modified starch and starch capsule products grew, achieving revenue of 56.41 million yuan, a year-on-year increase of 81.89% [2] Group 4: Research and Development - The company invested 1,993.37 million yuan in R&D in the first half of 2025, focusing on new pharmaceutical excipients and technology advancements [7] - The company is actively involved in the development of new drug excipients and enhancing existing ones [4] Group 5: Cash Flow and Accounts Receivable - The net cash flow from operating activities decreased by 64.08% in the first half of 2025, primarily due to reduced net purchases [6] - Accounts receivable reached 163 million yuan, a year-on-year increase of 51.44%, indicating a need for improved receivables management [6]

Core Viewpoint - The company is actively implementing the "Belt and Road" initiative, focusing on international expansion in Africa by leveraging local resources and Chinese industrial advantages [1] Group 1: Strategic Initiatives - The company has proposed a three-pronged market development plan for Africa, focusing on resource development, industrial empowerment, and technology output [1] - In Nigeria, the company aims to enhance lithium ore resource development by utilizing its existing lithium ore processing plant to create a supply chain for the new energy sector [1] - In Tanzania, the company plans to establish a modern processing base that utilizes local resources and advanced domestic production technology to produce specialty products for local markets and potential re-export to China [1] Group 2: Local Production and Collaboration - The company intends to set up a GMP-compliant pharmaceutical production base in Africa to export Chinese formulation technology and high-quality medicines, addressing local healthcare needs [1] - The strategy emphasizes deepening China-Africa cooperation through local employment, technical support, and infrastructure investment, aiming for a sustainable development model that combines resource complementarity, industrial synergy, and improved livelihoods [1]

Core Viewpoint - The company Erkang Pharmaceutical (300267) showcases its strengths and development potential in the pharmaceutical excipients industry during the 2025 Hunan Listed Companies Collective Reception Day and Semi-Annual Performance Briefing held on September 19. Group 1: Company Strengths - The company offers a diverse range of products, with 127 pharmaceutical excipient varieties, accounting for 32.87% of the 387 varieties listed in the 2025 edition of the Chinese Pharmacopoeia, covering nearly all commonly used pharmaceutical excipients [1] - Established supply relationships with over 3,000 domestic downstream customers, indicating high product and customer stickiness [1] - Possesses three significant research platforms: the "National Pharmaceutical Excipients Engineering Technology Research Center," the "National Recognized Enterprise Technology Center," and the "Key Laboratory of Pharmaceutical Excipients Engineering Technology of the National Medical Products Administration" [1] - Actively participates in the formulation and revision of standards for pharmaceutical excipients in the Chinese Pharmacopoeia and contributes to the compilation of the "Infrared Spectrum Collection of Pharmaceutical Excipients" [1] - Awarded the qualification of "Variety Guardian" for 12 types of pharmaceutical excipients by the National Pharmacopoeia Committee [1] - Achievements in quality improvement research for injectable pharmaceutical excipients, with the project "Key Technology Development and Industrialization of Injectable Pharmaceutical Excipients" winning the second prize in Hunan Province's Science and Technology Progress Award [1] - The company's starch capsules and other varieties have been included in the list of key varieties in the biopharmaceutical industry chain published by the Hunan Provincial Department of Industry and Information Technology (second batch) [1]

Group 1 - The core viewpoint of the article highlights the strategic initiatives of Erkang Pharmaceutical to enhance its market position in the raw material sector, particularly in customized services and product quality improvement [1] - In 2024, the company aims to integrate internal and external resources within the raw material sector and optimize its organizational structure to boost product quality and performance [1] - The sales volume of modified starch and starch capsule series products is expected to grow, achieving a revenue of 56.406 million yuan, representing a year-on-year increase of 81.89% [1] Group 2 - The sales revenue of injection auxiliary materials increased by 13.28% year-on-year, while the sales revenue of external preparation auxiliary materials grew by 29.87% [1] - The number of new customers developed for niacinamide remains steadily increasing, indicating a positive trend in customer acquisition [1]

Core Viewpoint - Hunan Erkang Pharmaceutical Co., Ltd. will participate in the 2025 Hunan Listed Companies Investor Online Collective Reception Day and Semi-Annual Performance Briefing to enhance interaction with investors [1] Group 1: Event Details - The event will be held online on September 19, 2025, from 14:00 to 17:00 [1] - Investors can participate through the "Panjing Roadshow" website, WeChat public account, or by downloading the Panjing Roadshow APP [1] - Company executives will communicate with investors regarding the company's performance for the first half of 2024 to 2025 and address investor concerns [1]

证券代码：300267 证券简称：尔康制药 公告编号：2025-026 湖南尔康制药股份有限公司 关于参加 2025 年湖南辖区上市公司投资者网上集体接待日 暨半年度业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，湖南尔康制药股份有限公司（以下简称 "公司"）将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有限公 司联合举办的"资本聚三湘 楚光耀新程——2025 年湖南辖区上市公司投资者网 上集体接待日暨半年度业绩说明会"活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 9 月 19 日（星期五）14:00-17:00。届时公 司高管将在线就公司 2024 年至 2025 年半年度业绩等投资者关心的问题，与投资 者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告！ 湖南尔康制药股份有限公司 2025 年 9 月 15 ...

Company Overview - Hunan Erkang Pharmaceutical Co., Ltd. is located in Changsha, Hunan Province, established on October 22, 2003, and listed on September 27, 2011. The company is engaged in the research, production, and sales of pharmaceutical products, primarily focusing on pharmaceutical excipients and new antibiotics [2]. Business Segmentation - The main business revenue composition includes: pharmaceutical excipients (36.29%), new energy materials (18.64%), composite excipients (16.21%), bulk excipients (14.62%), raw materials (6.88%), finished drugs (5.71%), and others (1.64%) [2]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 682 million yuan, representing a year-on-year growth of 9.74%. The net profit attributable to the parent company was 37.63 million yuan, showing a significant increase of 497.36% [2]. Stock Performance - As of September 15, the stock price of Erkang Pharmaceutical increased by 2.12%, reaching 3.85 yuan per share, with a trading volume of 119 million yuan and a turnover rate of 2.22%. The total market capitalization is 7.941 billion yuan [1]. - Year-to-date, the stock price has risen by 38.49%, with a slight decline of 0.52% over the last five trading days and a decrease of 5.64% over the last 20 days. However, it has increased by 24.19% over the last 60 days [1]. Shareholder Information - As of June 30, the number of shareholders reached 42,700, an increase of 4.40% from the previous period. The average circulating shares per person decreased by 4.22% to 33,275 shares [2]. - The company has distributed a total of 540 million yuan in dividends since its A-share listing, with cumulative distributions of 61.88 million yuan over the past three years [3]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited is the sixth-largest circulating shareholder, holding 21.56 million shares, an increase of 6.47 million shares compared to the previous period [3].

Group 1 - The company, Erkang Pharmaceutical (300267), focuses on the manufacturing of pharmaceutical excipients and is exploring the application of AI in drug discovery and formulation development [1] - The company is continuously monitoring relevant policy developments in the industry [1]

Group 1 - The company, Erkang Pharmaceutical (300267.SZ), stated that its main business includes the production and sales of excipients, raw materials, finished drugs, and new energy materials [1] - The company currently has no research and development projects related to "liver fibrosis drugs" [1]

Group 1 - The company has clarified that its core investigational heart failure drug is different from "HK-001" mentioned by investors [2] - The raw material research for the company's heart failure drug has been completed and is publicly listed on the National Medical Products Administration's platform [2] - The bioequivalence (BE) clinical trials for the formulation have been completed, and related work is ongoing [2]